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QT interval variation is assumed to arise from variation in repolarization as evidenced from rare Na- and K-channel mutations in
Mendelian QT prolongation syndromes. However, in the general population, common noncoding variants at a chromosome 1q locus
are the most common genetic regulators of QT interval variation. In this study, we use multiple human genetic, molecular genetic, and
cellular assays to identify a functional variant underlying trait association: a noncoding polymorphism (rs7539120) that maps within an
enhancer of NOS1AP and affects cardiac function by increasing NOS1AP transcript expression. We further localized NOS1AP to cardio-
myocyte intercalated discs (IDs) and demonstrate that overexpression of NOS1AP in cardiomyocytes leads to altered cellular electro-
physiology. We advance the hypothesis that NOS1AP affects cardiac electrical conductance and coupling and thereby regulates the
QT interval through propagation defects. As further evidence of an important role for propagation variation affecting QT interval in
humans, we show that commonpolymorphismsmapping near a specific set of 170 genes encoding ID proteins are significantly enriched
for association with the QT interval, as compared to genome-wide markers. These results suggest that focused studies of proteins within
the cardiomyocyte ID are likely to provide insights into QT prolongation and its associated disorders.Introduction
The electrocardiographic QT interval (MIM 610141), an
index of ventricular repolarization, is a moderately herita-
ble quantitative trait that has major medical significance
because prolongation or shortening of the QT interval is
associated with an increased risk of cardiovascular
morbidity and mortality.1,2 Extremes of the QT interval
are known to trigger ventricular tachycardia and ventricu-
lar fibrillation, which can lead to sudden cardiac death
(SCD).3 Genetic variation is one major source of QT inter-
val variation and genome-wide association studies
(GWASs) have identified at least 35 loci known to create
interindividual QT interval variability in individuals of Eu-
ropean ancestry (EA) (D.E.A., unpublished data).4–6
The locus with the largest contribution to cardiac repo-
larization variability, ~1% of population trait variation, is
one on chromosome 1q that contains the gene NOS1AP4
(MIM 605551), although its functional role in cardiac repo-
larization has not been proven. In neuronal tissues,
NOS1AP acts as a C-terminal PDZ domain ligand to
neuronal nitric oxide synthase (nNOS), probably regu-
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of NOS1AP in cardiac tissue remains unknown, the genetic
association between NOS1AP and the QT interval, repli-
cated in several studies,8–11 emphasizes its influence on
myocardial function. Importantly, the same QT-interval-
associated sequence variants at the NOS1AP locus are also
associated with ~30% increased risk of SCD in the general
population10,12 and are common genetic modifiers of
cardiac events in individuals with long QT syndrome
(LQTS)13,14 (MIM 192500). Taken together, these studies
implicate NOS1AP as the major genetic locus regulating
QT interval in the general population and as a susceptibil-
ity factor for cardiac arrhythmias and SCD.
Like all GWASs,15 the identity of the specific gene within
this locus, whether it is NOS1AP or not, and the specific
variant(s) that modulate the QT interval through this
gene remain unknown. Consequently, there is a major
gap between genetic findings and their molecular mecha-
nisms, resolution of which can illuminate a novel aspect
of cardiac biology. In this paper, we demonstrate, via a
variety of contemporary approaches, that the major gene
is indeed NOS1AP, that a functional variant lies within
an enhancer active in cardiac tissues, and that variableDepartment of Pathology, Johns Hopkins University School of Medicine,
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expression of NOS1AP in human heart depends on
polymorphism within this enhancer. In addition, we
physically localized NOS1AP to the cardiomyocyte interca-
lated discs (IDs), thereby explaining its role in cardiac
biology probably through effects on propagation rather
than repolarization. We further show that compared to
genome-wide polymorphisms, variants mapping near a
specific set of 170 annotated genes encoding proteins
that localize to IDs are enriched for association with the
QT interval, supporting our hypothesis that population
variability of QT interval is significantly regulated by the
ID and that genetic variation in its components can lead
to interindividual variation in the risk of cardiac arrhyth-
mias and SCD. Detailed studies of ID functions are now
necessary to understand how arrhythmias arise, sudden
death onsets, and the molecular bases of these complex
diseases.Material and Methods
Samples, Sequencing, and Variant Identification
A total of 46 subjects were selected for targeted sequencing from
a population-based survey of volunteers in the KORA cohort,16
in which the original GWAS was performed.4 Table S1 (available
online) provides the heart rate-, age-, and sex-corrected QT inter-
val measurements from these subjects.16 Eight CEU (NA06985,
NA06993, NA10839, NA10847, NA10859, NA11994, NA12003,
NA12006) and eight YRI (NA18486, NA18489, NA18502,
NA18505, NA18507, NA18517, NA18522, NA18523) HapMap
reference individuals17 were randomly selected for targeted
sequencing.
The target locus on human chromosome 1: 161,998,642–
162,139,683 (NCBI37/hg19)18 was 141,042 base pairs long and
encompassed exon 1, exon 2, intron 1, part of intron 2, and the
50 upstream region of NOS1AP (Gene ID: 9722; RefSeq accession
number NM_014697.2). The target region was recovered from
individual samples in 17 overlapping PCR amplicons. Primers
for amplifications were designed with Primer319 (Table S1). PCR
for individual amplicons in each sample was performed on
genomic DNA by TaKaRa LA Taq (Clontech) according to manu-
facturer’s recommendations. PCR products were gel-purified with
QIAquick and QIAEX II gel extraction kits (QIAGEN) and pooled
in equimolar amounts per sample. Preparation of short insert
paired-end libraries from amplicon pools and subsequent
sequencing were performed as described.20
Sequence reads were aligned to the target NOS1AP region by
cross_match21 and alignments were then converted to the BAM
format, a binary version of the Sequence Alignment/Map.22 For
single-nucleotide variant (SNV) and small insertion-deletion
(INDEL) genotyping, the Bayesian genotyper ‘‘bam2mpg’’23 was
used to call genotypes at each site for which there was at least
one read aligned; only genotypes with a MPG (most probable
genotype) scoreR10 were retained. To assess the level of coverage
required to discover all observed variants, we performed genotype
calling on reduced coverage subsets of the CEU samples’
sequencing data by random sampling of reads. A total of 108 small
INDELs were identified and all of these INDELs mapped to homo-
polymer runs or simple nucleotide repeats; the vast majority of
them were observed as singleton alleles (data not shown). GivenThe Amthe short sequence read data and limitations ofmapping and accu-
rately genotyping repetitive sequences, we did not use this type of
sequence variation in our subsequent studies.
We calculated allele frequencies for observed variants in the
KORA samples, but because of the relatively small sample size
and selection from extremes of QT interval we do not expect these
to be representative for the general population. However, we do
expect to find all common variants (R5% allele frequency)
with R99% certainty in sequencing of the 54 (108 alleles) CEU
and KORA samples.
To assess specificity of this sequencing-based approach, we
compared the sequencing-based genotype calls generated in the
eight CEU and eight YRI samples with the genotype calls from
HapMap17 (HapMapGenome Browser release #28). To assess sensi-
tivity, we calculated the proportion of HapMap polymorphic sites
within each sample that were identified by sequencing17 (HapMap
Genome Browser release #28).Imputation and Association Analysis to Identify
Candidate Causal Variants
Imputation and association analysis was performed in 9,055 indi-
viduals of EA from the ARIC (Atherosclerosis Risk in Commu-
nities) study,24 with genotypes from Genome-Wide Human SNP
Array 6.0 (Affymetrix) (henceforth labeled as Affymetrix 6.0
chip) and QT interval data.24 We used the BEAGLE genetic anal-
ysis software package25 for imputation of reference variants
discovered in this study by sequencing of KORA and CEU
samples and in the 1000 Genomes Project (1000GP)26 by
sequencing of CEU samples, based on 80 genotyped SNVs in
the NOS1AP region in ARIC24 samples. These 80 variants were
supplemented by first imputing an additional 872 variants iden-
tified in this study through de novo sequencing in 46 KORA and
8 CEU HapMap samples (total in both, 897; monomorphic, 25)
and then by an additional 39 variants reported only in the
1000GP_CEU pilot data26 catalog (1000GP Pilot data July 2010
release) but not discovered in KORA (total 439 variants in a
distributed haplotype file; 63 variants were filtered out by the
1000GP before haplotyping). Out of 911 genotyped and imputed
variants in 9,055 ARIC samples, 396 variants were monomorphic
after imputation and were subsequently removed before the asso-
ciation analysis. In addition, 3 more variants were removed as a
result of having a low imputation score (R2 < 0.8). A total of
512 variants passed quality control checks and were used in asso-
ciation analysis that was conducted in R (The R Project for Statis-
tical Computing) by regressing heart rate-, age-, and sex-corrected
QT interval residuals on variant genotypes. To test whether rare
variants were collectively associated with QT interval variation,
we performed a multiple regression with 92 ‘‘rare’’ variants and
tested their association by a global F-test. Here, ‘‘rare’’ was defined
as observing no variant-homozygous genotypes in the ARIC sam-
ples. The p value for this overall test was 0.12 showing the lack of
association, although statistical power to test this hypothesis is
probably low.Intersection of Variants with ENCODE Annotation
SNVs identified in the NOS1AP target region were uploaded into
the UCSC genome browser27 as custom tracks in BED file format
and intersected with ENCODE tracks28 via the UCSC table browser
tool.29 We specifically analyzed sequence variants for overlap with
DNaseI hypersensitive sites (DHSs) identified across cardiac cell
lines/tissues in the ENCODE project.28erican Journal of Human Genetics 94, 854–869, June 5, 2014 855
Luciferase Reporter Assays
To assess whether QT-associated variants influence cis-regulatory
elements (enhancers or silencers), variant alleles at selected
markers were subjected to luciferase reporter assays. The genomic
region flanking the variant site was amplified from the genomic
DNA of homozygous reference HapMap individuals and cloned
upstream of the SV40 promoter driving a firefly luciferase gene
in the pGL3-Promoter vector (Promega). The length of the
genomic region cloned, flanking the variant site, varied from
423 to 1,160 base pairs (Table S3) and was based on the extent
of conservation, presence of annotated functional elements from
ENCODE,28 and presence of repetitive sequences. Site-directed
mutagenesis (Stratagene) was used to generate the constructs
with alternate alleles. The identity of each construct clone was
verified by DNA sequencing.
For fine mapping of the cis-regulatory element encompassing
the 959 base pair long rs7539120_rs2010491 amplicon, several
different amplicons were subcloned by PCR and included
the following: (1) 742 bp long rs7539120_rs2010491 amplicon
(rs7539120_rs2010491_742), (2) 492 bp long rs7539120_
rs2010491 amplicon (rs7539120_rs2010491_492), (3) 709 bp
long rs7539120_rs2010491 amplicon with an internal deletion
of 250 bases (rs7539120_rs2010491_D250), and (4) 731 bp long
rs2010491 amplicon with deletion of rs7539120 (55 bases)
(Drs7539120_rs2010491_742). For each of these amplicons,
except (4), constructs carrying both alternate alleles were gener-
ated. Variant rs12143842 was re-evaluated in luciferase reporter
assays by the cloning of smaller inserts flanking the variant site
that included 623 and 325 bp amplicons (rs12143842_623 and
rs12143842_325) (Table S3).
The firefly luciferase constructs were transfected into HL1 cells30
and HEK293T cells (ATCC),31 grown in 24-well plates at ~90%
confluency by Lipofectamine-2000 (Invitrogen) according to
manufacturer’s protocols. pRLSV40 (Promega), expressing Renilla
luciferase, was cotransfected to normalize for transfection effi-
ciency. At 24 hr after transfection, cells were harvested and lysed
and firefly and Renilla luciferase activities were measured on a
VICTOR2 1420 Multilabel Counter (Wallac) with Dual-Luciferase
Reporter Assay System (Promega) according to manufacturer’s
protocols. Relative firefly luciferase activities were compared
between alternate alleles of a variant and to the empty vector
pGL3-Promoter-transfected cells to assess enhancer or silencer
function. Luciferase activity from each construct was measured
in four biological replicates, and each such experiment was
repeated twice (a total of eight biological replicates for each
construct in each cell line). Luciferase assays using the 959 bp
long rs7539120_rs2010491 haplotype constructs were addition-
ally performed in HL1 cells in eight biological replicates.In Vivo Enhancer Assays in Zebrafish
All protocols for zebrafish care and use were reviewed and
approved by the Institutional Animal Care and Use Committee
of Johns Hopkins University and zebrafish were cared for by
standard methods.32 The 742 base pair long risk haplotype
(rs7539120_rs2010491_742_H2), nonrisk haplotype (rs7539120_
rs2010491_742_H1), and the rs7539120 deletion (55 bases) risk
haplotype (Drs7539120_rs2010491_742_H2) inserts were cloned
upstream of a mouse cFos minimal promoter driving enhanced-
GFP (eGFP) in a tol2 transposon based reporter vector. Transposase
mRNA was in vitro transcribed with plasmid pDB600 (gift from S.
Mathavan, Genome Institute of Singapore, Singapore) as template856 The American Journal of Human Genetics 94, 854–869, June 5, 2and mMessage mMachine T3 kit (Ambion). For injections, 300 ng
of reporter plasmid, 250 ng of transposase mRNA (~50–100 pg/
embryo), and phenol red (0.1% final concentration) were com-
bined in a 10 ml volume and injected into wild-type AB strain
embryos at the 1–2 cell stage by a pico-injector (Harvard Instru-
ments). The empty reporter vector injections resulted in no
eGFP expression (data not shown). At 24 hr postfertilization
(hpf), eggs were moved to egg water containing phenylthiourea
to reduce pigmentation and allow better visualization of the
eGFP signal.nos1apa Expression in Zebrafish Embryos
At 24 hpf, 100 zebrafish embryos were collected, 50 of which
were used for RNA isolation from entire embryos and 50 of which
were used for RNA isolation from dissected heads versus the
remainder. Total RNA was isolated with TRIzol reagent (Invitro-
gen) according to manufacturer’s instructions. DNase treatment
and RNA clean-up was performed with RNeasy Mini kit and
RNase-Free DNase set (QIAGEN), according to manufacturer’s
instructions. cDNA was prepared by oligo-dT primer reverse
transcription from 200 ng of total RNA by SuperScript III First-
Strand Synthesis System (Invitrogen) according to the manufac-
turer’s instructions. One-tenth of the cDNA product was used
as a template in PCR using nos1apa exon 10/exon 11 spanning
primers (nos1apa_exon10F: 50-aagctggctggacaaggctct-30 and
nos1apa_exon11R: 50-ccaggcagaaagcgaaaacact-30) and actb1 exon
5/exon 6 spanning primers (actb1_exon5F: 50-cggtatccacgag
accaccttc-30 and actb1_exon6R: 50-agacggagtatttgcgctcagg-30).
PCR products were resolved by 2% agarose-TAE buffer gel
electrophoresis.Evaluation of rs7539120 as a Cardiac Expression
Quantitative Trait Locus
Samples of cardiac tissue were acquired from subjects from the
MAGNet consortium. All samples were collected with IRB-
approved protocols. Left ventricular free-wall tissue was harvested
at the time of cardiac surgery fromwhite subjects with heart failure
undergoing transplantation. The heart was perfused with cold
cardioplegia prior to cardiectomy to arrest contraction and pre-
vent ischemic damage. Tissue specimens were then obtained and
frozen in liquid nitrogen. Genomic DNA from left ventricle was
extracted with the Gentra Puregene Tissue Kit (QIAGEN) accord-
ing to manufacturer’s instruction. Genotypes at rs7539120 were
obtained by direct Sanger sequencing of PCR amplicons (959 bp)
(Table S3). Total RNA was extracted from left ventricle with the
miRNeasy Kit (QIAGEN) including DNase treatment on column.
RNA concentration and qualitywas determined with the NanoVue
Plus spectrophotometer (GE Healthcare) and the Agilent 2100
RNANanoChip (Agilent). cDNA synthesis by reverse transcription
on total RNA was performed as described above. NOS1AP expres-
sion was assessed by real-time quantitative PCR (qPCR) with
human-specific TaqMan Gene Expression assays (Applied Bio-
systems) for NOS1AP (Hs00928956_m1) and compared to RPL5
(Hs03044958_g1) (MIM 603634) as a housekeeping control.
qPCR was carried on 7900HT Fast Real-Time PCR System (Applied
Biosystems) and analyzed with Sequence Detection System Soft-
ware v.2.1 (Applied Biosystems). All samples were run in duplicate
and the DCT (negative delta cycle threshold) was used as the
measure of expression. For associations analysis, theDCTexpres-
sion value of 131 individuals with heart failure, as the dependent
variable, was regressed on rs7539120 genotypes (coded as 0, 1, 2).014
Conventional linear regression analysis was performed with
adjustment for age, sex, and study site.
Cardiac eQTL analysis, as described above, was also performed
with the MAGNet consortium-generated microarray gene expres-
sion data for all protein-coding genes (12) mapping 5500 kb of
rs7539120. Robust Multi-array Average expression values for
probes specific to the candidate genes and rs7539120 genotypes
from 89 individual samples were used for this analysis.
Electrophoretic Mobility Shift Assays
Complementary oligonucleotides encompassing rs7539120 alleles
and carrying deletion of rs7539120 (55 bases) were synthesized
(Integrated DNA Technologies), based on the genomic sequence
flanking the SNP (UCSC Genome Browser) (see Table S3 for
EMSA oligo sequences). For radiolabeled probes, complementary
oligonucleotides were annealed, and 5 pmol of double-stranded
DNA was labeled with 15 pmol of g-[32P]ATP (Perkin Elmer) with
20 U of T4 Polynucleotide Kinase (NEB). Unlabeled complemen-
tary oligonucleotides were annealed to create competitor probes.
Nuclear extract from HL1 cells was prepared with NE-PER Nuclear
and Cytoplasmic Extraction Kits (Pierce) according to manu-
facturer’s instructions. Radiolabeled probes (8,000 cpm) were
incubated with 4 ml of HL1 nuclear extract at RT for 20 min in
the presence of 10 mM Tris (pH 7.5), 50 mM KCl, 1 mM DTT,
1 mg poly(dI.dC), 2.5% glycerol, 0.05% NP-40, and 5 mM MgCl2
in a 20 ml reaction. Competitive binding assays were performed
under the same conditions, with the addition of 10 pmol of unla-
beled probe prior to the addition of the labeled probe. Protein-
DNA complexes were resolved on 8% native polyacrylamide gels
for 2 hr at 200 V in 0.53 TBE buffer, dried on a sheet of Whatman
3 paper (Whatman), and visualized by autoradiography.
Production of Lentiviruses for NOS1AP
Overexpression
Third generation lentiviral vectors were used for cellular NOS1AP
overexpression. Coding sequences of human NOS1AP long
isoform (RefSeq NM_014697) and short isoform (RefSeq
NM_001126060) were cloned as AgeI-SalI fragments into the
transfer plasmid pRRLsin18.cPPT.CMV.eGFP.Wpre vector (Inder
Verma, Salk Institute, San Diego; hereafter designated as LV-
eGFP), after the removal of eGFP, and the resulting plasmids
were designated as LV-NOS1AP-Long and LV-NOS1AP-Short.
Three third generation vectors, namely pMDLg/pRRE, pRSV-Rev,
and pMD2.VSV.G (Trono Didier), served as packaging plasmids
for lentivirus production. LVs were produced by transient cotrans-
fection of HEK293T cells as described.33
Cell Culture
HEK293T cells were maintained in DMEM culture medium
(Invitrogen) supplemented with 10% fetal bovine serum (FBS)
(Invitrogen), 100 U/ml penicillin (Invitrogen), and 100 mg/ml
streptomycin (Invitrogen). HL1 cells (gift fromW. Claycomb, Lou-
isiana State University) were maintained in Claycomb medium
(Sigma) as described.30 Neonatal rat ventricular myocytes
(NRVMs) were enzymatically disassociated from the ventricles of
2-day-old Sprague-Dawley rats (Harlan) via trypsin (Amersham
Biosciences) and collagenase (Worthington Biochemical). Freshly
isolated NRVMs were cultured as described.33 Two 90 min preplat-
ings were performed to reduce fibroblast counts and enrich for
cardiac myocyte content in the culture. The final cell suspension
was collected, counted for NRVMs, and plated at a concentrationThe Amof 0.5 million cells per 1 ml of medium. For mapping experiments,
1 million cells were plated on 21 mm plastic coverslips precoated
with fibronectin (25 mg/ml in water) at RT for 2 hr (Sigma). After
24 hr, coverslips were washed with warm phosphate-buffered
saline (PBS), and fresh medium with 10% FBS was added. After
48 hr, the culture medium was replaced with medium containing
2% FBS, and the cells were maintained in this 2% FBS-containing
medium, withmedium changes every second day. All protocols for
rat care, use, and euthanasia were reviewed and approved by the
Institutional Animal Care and Use Committee of Johns Hopkins
University and were in accordance with Association for Assess-
ment and Accreditation of Laboratory Animal Care (AAALAC)
guidelines.
Optical Mapping in NRVMs
Optical mapping studies were performed on NRVM monolayers
6–7 days posttransduction as described.33 To determine the action
potential duration (APD) at 80% repolarization (APD80) and
conduction velocity (CV), cells were stimulated with monophasic,
10 ms pulses at 2 Hz delivered by the stimulus electrode at twice
the diastolic threshold. A 2 s recording was taken after a 10-beat
drive train. Action potentials were recorded from 253 sites by a
custom-built contact fluorescence imaging system.33,34 With
multisite optical recordings of transmembrane potential, sequen-
tial maps of the activation patterns of NRVM cultures were
obtained, and normal and arrhythmic electrophysiological
behavior were monitored. Data were analyzed in MATLAB (The
MathWorks) with customized scripts.
NOS1AP Transcript Expression Profiling in Human
and Mouse Tissues
Real-time quantitative expression profiling of NOS1AP in 24
human and 20 mouse tissues was done with Multiple Tissue
cDNA (MTC) panels (Clontech) and TaqMan Gene Expression
assays (Applied Biosystems). cDNAs from Human MTC Panel I,
HumanMTC Panel II, Human Fetal MTC Panel, MouseMTC Panel
I, and Mouse MTC Panel III were assessed for NOS1AP expression
with human and mouse gene-specific TaqMan Gene Expression
assays (Human NOS1AP: Hs00928956_m1, Mouse Nos1ap:
Mm01290688_m1) according to manufacturer’s protocols. qPCR
was carried on as described above. Expression for each assay-tissue
combination was measured in technical triplicates and the aver-
ages of the threshold cycle (CT) values were used for analysis.
Because the purchased MTC Panels have been normalized to
several different housekeeping genes, the average CT values were
compared across tissues without any normalization against a
housekeeping gene’s expression level.
Anti-NOS1AP Antibody Generation
The production of a polyclonal antibody was contracted to the
Custom Immunology Services at Covance (Covance). Using a
peptide mapping to amino acid residues 486–503 of human
NOS1AP (NP_055512) as an immunogen, an affinity-purified rab-
bit polyclonal antibody was generated after a 118-day protocol.
Immunoblotting in Mouse Tissue Lysates
Nos1ap expression in various mouse tissues was evaluated
by immunoblotting with the rabbit polyclonal antibody we
generated. The tissues were dissected from an adult FVB mouse,
snap-chilled in liquid nitrogen, and stored at 80C until used.
All protocols for mouse care, use, and euthanasia were reviewederican Journal of Human Genetics 94, 854–869, June 5, 2014 857








Total # variants 474 614 880
In dbSNP Build 129 401 (85%) 408 (66%) 456 (52%)
Not in dbSNP Build 129 73 (15%) 206 (34%) 424 (48%)
In dbSNP Build 135 457 (96%) 576 (94%) 705 (80%)
Not in dbSNP Build 135 17 (4%) 38 (6%) 175 (20%)
Exonica 0 1 3
Coding 0 0 0
aAll exonic variants map to the 50 UTR of NOS1AP.and approved by the Institutional Animal Care and Use Commit-
tee of Johns Hopkins University and were in accordance with
AAALAC guidelines. Whole-tissue protein extracts from various
mouse tissue samples were prepared by homogenization of
~20 mg of tissue with a handheld homogenizer (Kinematica) in
modified RIPA buffer supplemented with protease inhibitor
cocktail (Roche). Tissue and cell debris were removed by centrifu-
gation, and the protein concentration was determined by Bio-Rad
DC Protein assay (Bio-Rad). Samples (200 mg) were denatured and
analyzed by immunoblotting according to standard methods.35
Immunohistochemistry in Formalin-Fixed Paraffin-
Embedded Human Heart Sections
FFPE sections of human heart tissue (6 mm) were single stained for
NOS1AP and double stained for NOS1AP andConnexin43, N-Cad-
herin, or Plakoglobin by standard methods. Tissue sections were
incubated with rabbit anti-NOS1AP polyclonal antibody alone
and simultaneously in combination with commercially available
mouse monoclonal antibodies against Connexin43 (Sigma),
N-Cadherin (Sigma), or Plakoglobin (Sigma). Anti-rabbit IgG-
HRP polymer conjugate was used for single-staining experiments.
For double-staining experiments, anti-mouse IgG-HRP and anti-
rabbit IgG-AP (alkaline phosphatase) polymer conjugates from
PicTure Double staining kit (Invitrogen) were applied simulta-
neously to the slides. ImmPact DAB (Vector Labs) and Fast Red
(Invitrogen) were used as chromogenic substrates for HRP and
AP, respectively. Tissue sections were counterstained with Harris
Hematoxylin (Sigma) and dehydrated and coverslips were
mounted with Cytoseal 60 Mounting Medium (Electron Micro-
scopy Sciences). Because of the presence of substantial auto-
fluorescence in FFPE heart sections, we did not use fluorophores
for colocalizations (data not shown).
Association between QT Interval and Variants
Mapping at Genes Encoding Proteins Localized at
Cardiomyocyte Intercalated Disc
The specific gene set, containing 170 autosomal genes whose pro-
tein products are localized at cardiomyocycte ID, was selected
from a systematic review of cardiac immunohistochemistry data
in the Human Protein Atlas (HPA) (with antibodies against more
than 5,000 human proteins) and the review on ID proteins by
Estigoy and colleagues.36 More than 27,000 polymorphisms
mapping in and around (510 kb) these genes were analyzed for
association with QT interval using data from a large GWAS858 The American Journal of Human Genetics 94, 854–869, June 5, 2(D.E.A., unpublished data) in >70,000 subjects of EA. A control
gene set of 166 autosomal genes, whose protein products are
observed in human heart but not localized to ID, were selected
by mining the HPA and more than 11,000 variants in and around
(510 kb) these genes were similarly analyzed for association
with QT interval. Quantile-quantile plots of association with QT
interval were generated and compared against (1) variants at the
specific ID gene set, (2) variants at the control heart expressed
gene set, and (3) genome-wide variants.Results
Saturation Sequencing of the NOS1AP Target Interval
Genetic associations are detected by the principle of link-
age disequilibrium (LD) across a genomic segment37 so
that further analyses are required to identify causal
variants. At a ~141 kb long genomic region flanking the
mapped NOS1AP locus,4 we attempted to create a near-
complete catalog of common variants by sequencing in
eight CEU and eight YRI HapMap17 reference samples
and in 46 subjects from the KORA cohort16 where we con-
ducted the original GWAS4 (Table S1). The target region
was selected as the genomic segment within which all gen-
otyped markers had p values above the significance
threshold in the original QT interval GWAS.4 DNA from
the target locus was recovered by long-range PCR and pool-
ing of 17 overlapping amplicons (Table S1) and direct
sequencing of the amplicon pool by Illumina technol-
ogy.20 In all samples, we obtained ~500-fold or greater
coverage across the target locus (Table S1, Figures S1A
and S1B); Figure S1C shows the number of variants
detected with increasing depth of sequence coverage. In
total, 1,063 SNVs were identified, all of which were non-
coding (Table S1). Table 1 shows a summary of the
sequence variation identified in each of the three groups
examined and Table S1 shows the minor allele frequency
distribution for the observed variation in KORA samples.
No coding variation at the target locus was observed in
the samples we sequenced, reflecting the high conserva-
tion of the NOS1AP coding sequence, and the variants
were randomly distributed with 319, 3, and 741 being
located in the upstream, 50 UTR, and introns 1–2 regions
of NOS1AP, respectively (Table S1).
We assessed the efficiency of de novo sequencing in
comparison to variants available in existing databases, an
important consideration if we are to census the causal
candidate sequence variants within this target locus. We
compared variants in the 46 KORA individuals with those
reported in the 85 1000GP CEU samples26 (1000GP May
2011 release): in brief, 682 SNVs were observed in the
1000GP_CEU versus 880 in KORA with an overlap of 566
variants, with 314 and 116 variants being unique to
KORA and 1000GP_CEU, respectively. The excess of
unique variants in KORA samples is most probably
improved detection resulting from the higher depth of
sequencing at a single ~141 kb locus (500-fold coverage)
in contrast to the low pass (4-fold coverage) across the014
Figure 1. Regional Association between
Variants at the NOS1AP Locus and QT
Interval in ARIC
The x axis shows the genomic interval
annotated with NOS1AP and OLFML2B
transcripts, the left y axis shows the statis-
tical significance of association as negative
log10 of p values, and the right y axis shows
the human recombination map based on
HapMap samples. The most significant
SNP, rs12143842, is shown as a purple
diamond, the functional SNP, rs7539120
(see Figure 2, below), is shown as a red
diamond, and the remainder are shown
as gray circles. The genomic interval corre-
sponding to the first major LD region (see
Figure S2B) is highlighted in light gray on
the x axis. The plot was generated with
LocusZoom.genome in the 1000 Genomes samples. Among the 314
variants unique to KORA samples, 175 variants were novel
(not reported in dbSNP Build 135, Table 1) and of which 19
had >10% allele frequency and so were common in our
study sample (Table S1); among the 116 variants unique
to 1000GP_CEU, only 4 variants had an allele frequency
>10%. Thus, de novo sequencing was necessary to identify
potential causal variants (Table 1). We next estimated the
specificity and sensitivity of de novo sequencing (Table
S1). More than 99.3% and 98.3% concordances for
sequencing-based genotype calls were observed in CEU
and YRI samples, respectively, when compared to existing
HapMap genotypes and more than 98.5% and 97.7%
variant detection sensitivity was observed in CEU and
YRI samples, respectively (Table S1).
Associations between NOS1AP Candidate Variants
and QT Interval
For association tests of variants with the QT interval
phenotype, we used 9,055 individuals of EA from the
population-based ARIC cohort24 in whom genome-wide
polymorphism data (Affymetrix 6.0 SNP array) were avail-
able.24 The NOS1AP target locus had 80 Affymetrix 6.0
SNPs (Figure S2A), which were used to impute and test a
total of 512 variants. We performed association analysis
with standard methods by regressing heart rate-, age-,
and sex-corrected QT interval residuals on variant geno-
types (Figure 1 and Table S2). Of the total 512 variants
assessed, 210 variants were strongly associated with QTThe American Journal of Humainterval and reached genome-wide
significance (p < 5 3 108) and
rs12143842 was the most significant
(p¼ 7.193 1022) (Figure 1 and Table
S2). This locus could be subdivided
into three broad regions based on pat-
terns of LD (LD blocks) (Figure S2B):
rs12143842 is located within the first
LD block and has a frequency of
~0.25. At least seven more variantswith similar frequencies (range: 0.221–0.251) and statisti-
cally significant p values (<4.09 3 1019) are in high LD
(r2 > 0.832) with the peak variant, based on analyses
within ARIC. To assess the specificity of the signal, we per-
formed a conditional association analysis by adjusting for
the effect of themost significant variant (Figure S2C). A sig-
nificant but relatively weaker association signal remained
at rs75642230 (p¼ 8.73 106) in the first LD block, which
based on LD is independent of the sentinel variant and not
in high LD with variants in the second or the third LD
blocks (Figure S2C). The conditional analysis therefore
revealed a major independent signal in the NOS1AP region
we targeted, confirming the results of our original GWAS,4
with rs75642230 capturing a secondary, relatively weaker
signal at the same locus; however, existence of other minor
variants cannot be excluded from these analyses. Addi-
tional associated polymorphisms do exist within the larger
~300 kb NOS1AP locus6 but are not considered here
because they map outside the peak association region of
~141 kb studied here; this strategy was adopted because
all QT interval association studies so far show that
rs12143842 is the most significant signal.
Annotation of Polymorphisms for Functional
Analyses
All of the 210 common variants associated with QT inter-
val at the NOS1AP locus were noncoding, indicating the
plausibility that variation within a cis-regulatory func-
tional element regulates gene expression and underliesn Genetics 94, 854–869, June 5, 2014 859
Figure 2. rs7539120 Is a Functional Variant Underlying QT Interval Association at the NOS1AP Locus
(A) Firefly luciferase reporter enhancer/silencer assays in HL1 cells using alternate alleles/haplotypes for selected QT-interval-associated
NOS1AP variants. Firefly luciferase expression is plotted relative to Renilla luciferase expression, normalized to the expression from
empty vector (Promoter). Mean luciferase expression between alternate alleles/haplotypes constructs was compared with the t test
and found to be significantly different between rs2010491 haplotypes, which also include rs7539120 alleles (p ¼ 3 3 105). Error
bars indicate SEM (n ¼ 8).
(legend continued on next page)
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QT interval variation, although other mechanisms (e.g.,
miRNA, ncRNA, etc.) underlying noncoding variation
function are possible. Among the various functional
annotations of the human genome,28 we focused on
DNaseI hypersensitivity (DH) because it is an in vivo indi-
cator of enhanced chromatin accessibility and is a univer-
sal hallmark of active cis-regulatory sequences.38 Because
NOS1AP is widely expressed in human tissues (see below),
we restricted our analysis to DH maps generated in the
following human cardiac tissues and cell lines: human
heart (Heart_OC; frozen tissues retrieved from autopsy
and surgery) and three cardiac primary cell lines, namely
HCF (human cardiac fibroblasts), HCFaa (human cardiac
fibroblast, adult atrial), and HCM (human cardiac myo-
cytes).39,40 In the NOS1AP target interval, there are 5, 10,
10, and 18 DHSs41,42 covering 1.68 kb, 1.61 kb, 1.69 kb,
and 2.91 kb in Heart_OC, HCF, HCFaa, and HCM samples,
respectively (Figure S2D). The combination of these four
maps led to identification of 21 cardiac DHSs covering
4.6 kb of the target interval. Among the 210 QT-interval-
associated variants, 5 sequence variants map to these car-
diac DHSs and were selected for functional assessment
(Figure S2D). To broaden our search, we also evaluated
genome-wide binding profiles of enhancer-associated
coactivator protein p300 and the closely related CBP coac-
tivator protein43 in human heart tissue.44 However, there
were no p300/CBP-bound regions in the NOS1AP target
interval.
Enhancer/Suppressor Analysis of Selected Variants
Identifies a Functional Variant Underlying QT
Interval Association
We used two criteria for selecting 12 QT-interval-associated
variants for functional analyses: (1) rs12143842 (the
sentinel variant) and all other variants in high LD with
it; and (2) all variants mapping to cardiac DHSs defined
above (Table S3). At each variant, alternate alleles were
cloned into luciferase reporter constructs and evaluated
for differential enhancer/suppressor activity via transient
assays in the mouse cardiomyocyte cell line, HL1.30 We
also used the human embryonic kidney cell line
HEK293T31 as a noncardiac cell line for these reporter(B) Enhancer activity in rs7539120_rs2010491 haplotype is driven by
erase reporter enhancer/silencer assays in HL1 cells using a deletion
the construct design on left, small vertical lines represent the rs75391
passing rs7539120, 50 deletions are represented by shorter lengths of
by sloping lines. Error bars indicate SEM (n ¼ 8).
(C) rs7539120 acts as an in vivo enhancer. The rs7539120 risk haplot
cell stage in developing zebrafish embryos drives transient reporter ex
in ~33% of injected embryos. Representative images from four diffe
expression indicated by yellow arrows) are shown. No eGFP expressio
(Drs7539120_rs2010491_742_H2) (see Figure S4). Abbreviations are
(D) rs7539120 acts as a cardiac expression quantitative trait locus (eQ
ventricle tissue from 131 heart failure subjects genotyped at rs753912
allele T is associated with higher expression of NOS1AP (p ¼ 4.72 3
(E) rs7539120 is bound by an uncharacterized protein(s) from HL1 ce
nonrisk allele (A), risk allele (T), and deletion (D) of rs7539120 in
unlabeled competing probe (C). The black arrow indicates DNA-prote
but lacking with the deletion probe. þ indicates addition; - indicates
The Amassays. Three variants (rs12123681, rs7366599, and
rs12123710), because of their close proximity, were ampli-
fied and tested together (referred to as the rs12123710
construct hereafter); however, variant rs7366599 within a
homopolymer stretch of adenine bases was not recovered
during amplification and not tested in reporter assays.
Genomic regions flanking rs12123710, rs2010491, and
rs945708 cloned for reporter assays included additional
common variants and were tested as QT-prolonging (risk)
and QT-reducing (nonrisk) allele-carrying haplotypes.
The insert for rs12123710 included rs1415268, the insert
for rs2010491 included rs7539120, and the insert for
rs945708 included rs10918762. These three additional
variants were also genome-wide significant for QT interval
association (Table S3).
Across all variants tested in both cell lines, only the
rs7539120_rs2010491 haplotype constructs showed a
small (1.19-fold) but consistent (8 biological replicates)
and significant (p ¼ 3 3 105) differential allelic activity
in HL1 cells (Figures 2A and S3A). On repeating reporter
assays for the rs7539120_rs2010491 haplotype constructs
in HL1 cells, in another set of 8 biological replicates, we
obtained similar results (1.19-fold, p ¼ 9.5 3 104)
(Figure S3B), indicating that the differential allelic activity
is consistent. The risk allele haplotype rs7539120T_
rs2010491G (haplotype 2; H2) had increased reporter
expression as compared to the nonrisk allele haplotype
rs7539120A_rs2010491A (haplotype 1; H1), so that we
needed to test whether one or the other or both variants
were responsible for the differential transcriptional
activity. The insert size used for the rs7539120_
rs2010491 haplotype construct was 959 bp. To refine
the functional element driving enhancer activity, we
created a series of deletion constructs and evaluated
them for reporter expression in HL1 cells (Figure 2B and
Table S3). A 217 base long deletion from the 50 end
(rs7539120_rs2010491_742) led to increased differential
enhancer activity (1.5-fold; p ¼ 6.7 3 106). Deletion of
rs7539120 (55 bases) in the risk allele haplotype
(Drs7539120_rs2010491_742) reduced the expression
to levels similar to the nonrisk allele haplotype, indicating
that rs7539120 is the functional variant driving enhancerrs7539120 and is dependent on the flanking sequence. Firefly lucif-
series derived from the 959 bp rs7539120_rs2010491 construct. In
20 and rs2010491 SNPs, D represents the 11-base deletion encom-
the horizontal line, and an internal 250 bp deletion is represented
ype construct injected (rs7539120_rs2010491_742_H2) at the 1–2
pression (enhanced-GFP; eGFP) in forebrain 24 hr postfertilization
rent embryos with forebrain eGFP expression (white spots, strong
n was observed from the rs7539120 deletion (55 bases) constructs
as follows: FB, forebrain; YS, yolk sac.
TL). Box-whisker plots of NOS1APmRNA expression in human left
0. The y axis shows –DCTused as a measure of expression. The risk
105).
ll nuclear extract. EMSAs using radiolabeled probes (P) containing
presence or absence of HL1 cells nuclear extract (NE) and excess
in complex formedwith both the A and Talleles containing probes,
absence.
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activity in the rs7539120_rs2010491 haplotype construct.
A longer 467 base deletion from the 50 end (rs7539120_
rs2010491_492) led to increased reporter expression
from both haplotypes but with no significant allelic
difference. These experiments indicated that (1) the bases
218–467 (250 bases) of the 959 bp construct carry an
enhancer element that increases expression from the
rs7539120 risk allele only, (2) the bases 1–217 of
the 959 bp construct carry a repressive element, and (3)
the internal 250 base enhancer element is necessary to
drive enhanced expression from the rs7539120 risk
allele. Consequent to this prediction, we can indeed
demonstrate that internal deletion of bases 218–467
from the 959 bp construct (rs7539120_rs2010491_D250)
leads to similar reporter expression from both haplotypes.
We also evaluated the sentinel variant rs12143842 in
reporter assays by using smaller inserts (623 and 325 bp,
Table S3) to identify any insert-size-dependent allelic
difference in reporter expression; unlike the rs7539120
variant, no significant allelic expression difference could
be observed (Figure S3C). Together, these results show
that despite the peak association being at rs12143842,
the functional variant is probably rs7539120 whose
in vitro enhancer activity is flanking sequence dependent
(Figure 2B).
A direct hypothesis from the above results is that
rs7539120 is located within an enhancer element. First,
we directly evaluated the potential of the rs7539120
variant to act as an enhancer in vivo by using transient
developmental enhancer assays in zebrafish embryos. For
this, the 742 bp long risk (rs7539120_rs2010491_742_H2)
and nonrisk (rs7539120_rs2010491_742_H1) haplotypes
and the rs7539120 deletion (55 bases) risk haplotype
(Drs7539120_rs2010491_742_H2) inserts used in in vitro
assays (above) were cloned into minimal promoter driven
eGFP reporter constructs and injected into developing
zebrafish embryos at 1–2 cells stage and observed for
eGFP expression 24 hr postfertilization. The risk allele
haplotype drove eGFP expression in forebrain from ~33%
of injected embryos (Figure 2C and Table S3). The nonrisk
allele haplotype also drove eGFP expression in forebrain
from ~25% of injected embryos (Figure S4A and Table
S3). As expected in transient expression assays, low levels
of mosaic expression was also observed. No eGFP expres-
sion was observed from the rs7539120 deletion construct
(Figure S4A), thus indicating that the rs7539120 variant
site and the flanking sequence is necessary for in
vivo enhancer activity. We also compared the observed
in vivo transient enhancer activity of the rs7539120_
rs2010491_742 construct with nos1apa endogenous
expression in wild-type zebrafish embryos 24 hpf. We
could not detect nos1apa expression by RNA in situ hybrid-
ization. However, by RT-PCR, nos1apa expression was
observed in the head region and in the remainder of the
body from zebrafish embryos as well as in whole embryos
(Figure S4B), indicating that nos1apa is expressed at rather
low levels not detectable by in situ. Thus, the in vivo862 The American Journal of Human Genetics 94, 854–869, June 5, 2enhancer activity observed for rs7539120 construct in
transient zebrafish assays overlaps nos1apa expression
domains.
Based on the transient in vivo enhancer activity of
rs7539120 we observed, the alternate alleles at rs7539120
are expected to demonstrate expression differences in
the human heart. Consequently, we measured NOS1AP
mRNA levels in human left-ventricular heart tissue
obtained from 131 EA subjects with heart failure whom
we genotyped for rs7539120. There is no a priori evidence
for the NOS1AP locus influencing the risk for heart failure,
so the disease state of study subjects is not expected to
influence NOS1AP expression. NOS1AP mRNA expression
levels were measured by reverse transcriptase-quantitative
PCR and rs7539120 was genotyped by direct Sanger
sequencing. As predicted, a significant, albeit small, in-
crease in NOS1AP mRNA expression was observed with
each copy of the risk allele T at rs7539120 (p ¼ 4.72 3
105) (Figure 2D). The same effect of enhanced expression
with the risk allele T at rs7539120 was observed in in vitro
luciferase reporter assays (above) and therefore shows con-
sistency between the in vitro and in vivo effects.
We also evaluated rs7539120 as a cardiac eQTL for
expression of other protein-coding genes nearby. Besides
NOS1AP, there are 11 protein-coding genes within
5500 kb of rs7539120. With the MAGNet-consortium-
generated cardiac microarray gene expression data from
89 EA samples for which we also had rs7539120 genotypes,
eQTL analysis ruled out all but NOS1AP as candidate genes
at this locus. Although, based on microarray gene expres-
sion data, 8 had cardiac expression, NOS1AP was the
only gene whose cardiac gene expression was significantly
(p ¼ 1.4 3 103) influenced by the rs7539120 genotype
(Table S4).
These data support our hypothesis that rs7539120 lies
within a cardiac enhancer element. As further evidence
we performed EMSAs for both the rs7539120_T risk allele
and rs7539120_A nonrisk allele carrying short duplexes
(43 bp). These were found to be bound by an uncharacter-
ized protein(s) from HL1 cell nuclear extract, although
there is only a small difference in allele-specific binding/
shift, a feature common to many, but not all, such allele-
specific EMSA assays. However, an 11 base deletion encom-
passing the variant site abrogated this DNA-protein
complex, indicating that the variant base and the flanking
sequence act as the binding site (Figure 2E). Consequently,
although support for the enhancer hypothesis is strong,
the exact nature of the bound cardiac protein is currently
unknown.
NOS1AP Regulates Cardiac Cellular Electrophysiology
The genetic results described above, together with expres-
sion differences at NOS1AP, suggest that NOS1AP is indeed
the basis for QT interval association. To prove its further
functional involvement, we next sought direct evidence
by altering NOS1AP expression and demonstrating cellular
electrophysiological differences in a surrogate system. Two014
Figure 3. Expression Levels of NOS1AP
Influences Cardiac Electrophysiology
(A) Left: Representative APD (in millisec-
onds, ms) trace at 80% repolarization
(APD80) in NRVMs nontransduced (top)
and transduced with human NOS1AP short
(middle) and long (bottom) isoforms,
respectively. Overexpression of both iso-
forms of NOS1AP in NRVMs lead to sig-
nificantly reduced APD80, as compared to
nontransduced cells. Right: Bar plots
showing mean APD80 from four replicates.
Error bars indicate standard deviation and
asterisks indicate p < 0.05.
(B) Representative isochronal maps for CV
(in cm/s) in monolayer of NRVMs non-
transduced (top left) and transduced with
human NOS1AP short (top right) and long
(bottom left) isoform, respectively. Over-
expression of both isoforms of NOS1AP in
NRVMs leads to significantly increased CV,
as compared to nontransduced cells.
Bottom right: Bar plots showing mean CV
from four replicates. Error bars indicate
standard deviation and asterisks indicate
p < 0.05.previous studies, prompted by our original genetic screen,4
provide some evidence for a possible role of NOS1AP in
regulating cardiac electrophysiology. In a prior collabora-
tive study we demonstrated that morpholino-based knock-
down of zebrafish nos1ap leads to shortened APD in
excised hearts from developing embryos.45 Second, over-
expression of guinea pig Nos1ap in guinea pig ventricular
myocytes by in vivo gene transfer leads to shortened
APD mediated by inhibition of L-type calcium current.46
These two studies, although performed in different model
systems, indicate seemingly opposite directions of effect.
Consequently, we evaluated the role of NOS1AP in cardiac
cellular electrophysiology with NRVMs as a model sys-
tem.47 Overexpression of both long and short isoforms of
human NOS1AP led to a significant decrease in APD
(Figure 3A) and a significant increase in CV measured
across the monolayer of cultured NRVMs (Figure 3B), asThe American Journal of Humcompared to nontransduced cells.
These results are consistent with the
findings of Chang et al.46 in other
mammalian cardiac cells and show
that NOS1AP expression level directly
affects cellular electrical properties.
NOS1AP Localizes to Intercalated
Discs in Cardiac Muscle
NOS1AP transcript and protein are
widely expressed as determined from
TaqMan-based quantitative PCR (Fig-
ures S5A and S5B) and immuno-
blotting (Figure S5C). Thus, as a clue
to its cellular function, we assessed
cellular localization of NOS1APby immunohistochemical staining of formalin-fixed
paraffin-embedded (FFPE) sections of human hearts with
a custom rabbit polyclonal NOS1AP antibody. Strikingly,
and as opposed to the published literature based on
commercial antibodies, NOS1AP was mostly localized to
ID joining cardiomyocytes (Figure 4A). To confirm this
localization, we performed dual immunohistochemical
staining for NOS1AP and three well-localized cardiac
ID marker proteins, representing each of the three well-
recognized structural zones within the ID, namely gap
junctions, desmosomes, and fascia adherens.36 By light
microscopy, NOS1AP was found to colocalize with all
three ID marker proteins, namely Connexin43 (Gap junc-
tions), N-Cadherin (Fascia adherens), and Plakoglobin
(Desmosomes) (Figure 4B), pointing to its broader distribu-
tion throughout the ID and probably a broader functional
role.an Genetics 94, 854–869, June 5, 2014 863
Figure 4. NOS1AP Localizes to ID in
Cardiac Muscle
(A) Immunohistochemical staining of
FFPE section of human heart (left ventricle
free wall) with NOS1AP antibody. Intense
staining (dark brown) was observed at ID
joining adjacent cardiomyocytes.
(B) NOS1AP colocalizes with proteins
marking the three well-recognized struc-
tural zones within the ID: desmosomes,
gap junctions, and fascia adherens. Immu-
nohistochemical staining of FFPE section
of human heart with an antibody against
an ID marker protein (Plakoglobin at
desmosomes, top; Connexin-43 at gap
junctions, middle; andN-cadherin at fascia
adherens, bottom) alone (left column) and
in combination with NOS1AP antibody
(right column).Intercalated Disc Proteins Play a Significant Role in
QT Interval Regulation
The localization of NOS1AP, the major genetic regulator of
QT interval trait variation, at cardiomyocyte ID presents a
very attractive and testable functional hypothesis for QT
interval variation. It is possible that, as currently believed,
most QT interval variation arises from variation in repolar-
ization components (Na channels, K channels, and
proteins that regulate such channels directly) and that
NOS1AP is the exception being localized at the ID. Alterna-
tively, it’s likely that the ID plays a major role in QT inter-
val variation but through variation in propagation. We,
therefore, assessed whether sequence variation at genes
whose protein products are localized to the ID contributes
to QT interval variation. To do so, a specific ID gene list of
170 genes (Table S5) was selected from a systematic re-
view36 based on cardiac immunohistochemical data in
the HPA; a control-heart-expressed gene list of 166 genes,
whose protein products are observed in the heart but not864 The American Journal of Human Genetics 94, 854–869, June 5, 2014localized at the ID, was selected by
mining HPA (Table S5). We compared
both against the results from a recent
large GWAS for QT interval in
>70,000 EA subjects performed by
the QT Interval-International GWAS
Consortium (QTIGC) (D.E.A., unpub-
lished data). As Figure 5 clearly shows,
using quantile-quantile (QQ) plots,
the combined effect of variants in
and around the 170 ID genes show a
considerably higher enrichment for
association than the genome-wide
comparison. The parsimonious
reason for this finding is the relatively
higher proportion of QT-interval-
affecting genes in the ID than the
whole genome. This enrichment re-
mained even after removing the
known and major effect of NOS1APand this specific effect was not observed for variants in
and around the control-heart-expressed genes (Figure 5).
Thus, the combined effect of ID genes, implicated by the
finding of NOS1AP, is highly significant and shows the
important role of the cardiomyocyte ID in the population
variability of the QT interval. This suggests that propaga-
tion defects, like repolarization defects, are an important
source of QT interval prolongation and sudden cardiac
death.Discussion
GWASs have been an effective screen for common poly-
morphic markers that underlie genetic variation of quanti-
tative traits and complex diseases.48 Nevertheless, at least
so far, they have been ineffective in directly leading to a
deeper understanding of either quantitative trait genetic
architecture or the pathophysiology of common and
Figure 5. Genes Encoding Proteins Localized at Cardiomyocytes
ID Play a Significant Role in Interindividual QT Interval Variation
QQplots of QT interval GWAS, and association studies of QT inter-
val using a specific set 170 ID genes and NOS1AP, and a control set
of 166 heart-expressed genes not localized at ID. The black, blue,
green, and red curves show the QQ plots for all GWASs, ID genes
includingNOS1AP, ID genesminusNOS1AP, and the control heart-
expressed genes. The gray line shows the expected values from a
theoretical c2-distribution. For each gene we selected variants in
and around (510 kb) the gene from the GWAS. The y axis has
been truncated at 35.chronic human disease. Except for a few examples where
association mapping has led to the tacit implication of a
nearby gene as a novel disease hypothesis, such as dysregu-
lated complement function in age-related macular degen-
eration49 (MIM 603075) or autophagy in Crohn disease50
(MIM 266600), in the vast majority of cases it is not clear
which of the many genes close to the associated polymor-
phism(s) is the functional molecule nor which of themany
common variants is (are) the causal factors nor the molec-
ular basis of the observed association. Although GWAS
results are presented with a nearby gene as the candidate
pro tem, this choice is fictive and requires functional
data demonstrating its role in that trait or disease.51 In
this study, we use a variety of functional analyses to
not only implicate a gene but also demonstrate how its
cellular localization both suggests a pathophysiological hy-
pothesis and pinpoints functional candidates not known
previously.
In this study, we have undertaken a genetic dissection of
a primarymarker of cardiac repolarization, the QT interval.
Our original GWAS identified NOS1AP as the locus with
the single largest genetic contribution to interindividual
trait variation4–6 and, subsequently, we demonstrated
that these same polymorphisms significantly increased
the risk for SCD in the general population10,12 and that
they also acted as potent genetic modifiers of the LQTS
phenotype in individuals with known Na and K channelThe Ammutations.13,14 We report here the identification of
rs7539120 as one of the functional noncoding variants
affecting QT interval variation and provide evidence that
NOS1AP is indeed the underlying gene at the associated
locus whose expression levels influence cellular electro-
physiology. And, based on NOS1AP localization at the ID
in human cardiac muscle, we hypothesize that NOS1AP
affects cardiac electrical conductance and coupling and
thus regulates the QT interval. Identification of NOS1AP
as a major genetic regulator of QT interval variation, a
gene not previously known to influence cardiac repolariza-
tion, thus leads us to a new perspective of QT interval
biology.
The localization of NOS1AP to ID opens the way
to assess its detailed cellular function, how it regulates car-
diac repolarization, and its role in sudden death and other
conduction disorders. Interestingly, (1) these functions are
not solely attributable to NOS1AP—our QT interval GWAS
identifies other loci as well (D.E.A., unpublished data),5,6
(2) the LQTS genetic modification suggests interaction
with cardiac Na and K channels,13,14 and, most crucially,
(3) the ID harbors many other proteins whose genetic
variation also affects the QT interval (Figure 5). Conse-
quently, we advance the hypothesis that one or more
proteins at the ID, including NOS1AP, regulate ion flow
through the cardiomyocyte gap junctions. A consequence
of this hypothesis is that many of these ID proteins can
now be directly tested and implicated both in modulating
population-level QT interval variation and the risk of SCD
likely through propagation defects. This implication, as
shown in Figure 5, would be impossible without GWAS
data and it is this use of testing functional hypotheses
directly that will make the expanding catalogs of GWASs
valuable. By restricting attention to variants that map
near a functionally enriched set of genes encoding pro-
teins that localize to ID, we were able to identify associa-
tions with the QT interval that were missed in the
GWAS. Specifically, at false discovery rates of 5% and
1%, we identified 27 and 14 ID genes, respectively, which
is a large yield of novel functional candidates. Although
these genes need to be further investigated, two exemplars
are PTK2 (MIM 600758) and SIPA1L1. PTK2 (protein tyro-
sine kinase 2) encodes focal adhesion kinase (FAK), a
broadly expressed nonreceptor protein-tyrosine kinase,
which is concentrated at focal adhesions and regulates
many cellular processes in development and disease.52
Specifically, in cardiomyocytes, sarcomeric myosin inter-
acts with FAK to regulate FAK activity and has an impact
on the control of cardiomyocyte growth in response to hy-
pertrophic stimuli.53 SIPA1L1 (signal-associated prolifera-
tion-associated 1 like 1) encodes a Rap GTPase activating
protein that plays a role in noncanonical Wnt signaling
and contributes to development.54 Interestingly, common
variants at SIPA1L1 locus have been reported to be associ-
ated with QRS interval duration, an indicator of ventricu-
lar depolarization, in a large GWAS of more than 40,000
subjects.55erican Journal of Human Genetics 94, 854–869, June 5, 2014 865
The major role of NOS1AP as a QT interval regulator
together with the GWAS of other electrocardiographic
(ECG) traits, including QT interval, have clearly high-
lighted the role of non-ion-channel proteins in cardiac
electrophysiology. Biochemically, Na channels, K chan-
nels, and Ca-handling proteins have been known as the
major mediators of cardiac de- and repolarization, but ge-
netic studies in contrast have shown that variation in these
channel proteins explain only a minor portion of the trait
variance, probably owing to their highly conserved struc-
tures and functions. Indeed, the major sources of genetic
variation in ECG traits are non-channel proteins that prob-
ably regulate cardiac electrical cycle indirectly by influ-
encing ion channel expression, localization, and function.
Or, they probably affect propagation as opposed to de- or
repolarization. Therefore, the role of the ID may not
simply be structural, as usually assumed, but as a rich
signaling domain in cardiomyocytes that influences the
expression of structural proteins and proteins involved in
metabolism as well as electrical excitability.
Our study also has implications for the nature of GWAS
variants. The QT-interval-associated functional variant,
rs7539120, is a noncoding variant and has an allele
frequency of 0.42 (risk allele; T) in directly genotyped EA
samples (n ¼ 273) from the MAGNet consortium. The
functional enhancer activity of this variant is dependent
on the flanking sequence, and deletion experiments
show that this variant site demonstrates both consistent
and necessary enhancer activity in vitro and in vivo.
Also, this variant site is bound by a nuclear protein from
HL1 cells, yet uncharacterized, which will provide further
clues to NOS1AP function. Surprisingly, the enhancer
variant shows only moderate LD (r2 ¼ 0.44) with the orig-
inal discovery sentinel variant rs12143842, which has a
significantly lower allele frequency of 0.26 (risk allele; T)
in directly genotyped EA samples (n¼ 273). These observa-
tions are explained by the monophyletic origin of
rs12143842 but the polyphyletic origin of rs7539120, the
latter occurring on multiple haplotypes, only some of
which contain the sentinel variant. This genetic outcome
is not unexpected because the functional variant
rs7539120 maps to a simple sequence repeat (SSR) (TA)n
that we hypothesize leads to increased hypermutability,
its multiple origins, and only moderate LD with the
sentinel variant. It is important to note that there is
growing evidence supporting the role of SSRs as a source
of qualitative and quantitative genetic variation and that
SSRs coevolve with the genes they are associated with to
influence gene regulation, transcription, and protein func-
tion.56,57 Given the widespread occurrence of such repeti-
tive sequences in the human genome, this type of
enhancer is unlikely to be an isolated example. This im-
plies that contemporary databases of noncoding func-
tional elements (ENCODE28) that are deficient in repeated
sequences may miss these elements.
The existence of multiple independent association
signals of varying significance at any given locus is not866 The American Journal of Human Genetics 94, 854–869, June 5, 2uncommon and has been reported in several GWASs. In
our study, association analysis conditional on the sentinel
variant rs12143842 revealed the presence of a secondary,
relatively weaker association signal captured by
rs75642230 (p ¼ 8.7 3 106) (Figures S2C and S6A). Asso-
ciation analysis conditional on both the functional variant
rs7539120 and the sentinel variant rs12143842 reveals the
weaker secondary signal at rs75642230 (p ¼ 1 3 105)
(Figure S6B); conditioning on these three variants
completely removes the association signal at this locus
(Figure S6C). These analyses indicate that rs12143842 is
the major signal at the QT-interval-associated NOS1AP
locus and that rs75642230 captures an independent, rela-
tively weaker signal at the same locus.
Because rs7539120 is located in a repeat region and
was imputed for association analysis, we evaluated the
accuracy of imputation by directly genotyping rs7539120
by PCR followed by Sanger sequencing in 367 ARIC sam-
ples, which were a subset of 9,055 ARIC samples in which
imputation and association was performed. The overall
match with imputation calls was 85.6%: these match fre-
quencies were 98.5%, 81.3%, and 65.3% for the AA, AT,
and TT genotypes, respectively. This would indicate that
imputation, which is based on 1000 Genomes reference
haplotypes, is undercalling the risk allele T, and thus the
mismatch rate is highest for TT genotypes; in other words,
the ‘‘reference’’ genotypes are not highly accurate. This
makes it likely that the 1000 Genomes reference haplo-
types have an underrepresentation of T (risk) allele-
carrying haplotypes. Based on these observations, we
would conclude that the true association of rs7539120
with the QT interval is higher than what is observed based
on imputation in ARIC samples. This is another reason for
the apparent lower association of the functional SNP in
contrast to the sentinel marker. We also genotyped
rs12143842, the sentinel QT-interval-associated SNP, by
TaqMan assay in 278 ARIC samples and found the overall
match with imputation calls to be 98.9%, indicating that
low imputation accuracy for rs7539120 is most likely due
to it being in a repeat region.
Our QT interval study demonstrates that replicated
genetic associations are almost invariably noncoding,
even for loci where the functional candidate gene is clear
such as those for the known LQTS Na and K channel genes
or the Ca pump regulator phospholamban (PLN). Because
the cardiac phenotypes of disruptive coding mutations in
these genes are well described,3,58 the overall evidence
(hypothesis) for population QT interval variation is that
it arises from variation in levels of wild-type (not mutant)
protein. Consequently, we propose it is likely that QT
interval variation arises from variation in the stoichiom-
etry of specific regulatory proteins—but which ones? QT
interval GWASs have implicated at least 35 loci in our
recent studies (D.E.A., unpublished data), but which spe-
cific genes and variants do they represent? Functional an-
alyses such as the ones we report here will be necessary
and can be performed in higher throughput by using014
parallel cellular electrophysiology studies of gene knock-
down or overexpression in NRVMs (Figure 3), sequence
variant catalogs,26 and new high-throughput sequencing-
based in vitro and in vivo assays of noncoding regulatory
function.59,60 As an alternative approach, we could have
used DNA sequence conservation across multiple species
to prioritize variants.61–63 However, conservation of regu-
latory function is not always reflected in sequence con-
servation.28,64 Moreover, many cis-regulatory elements,
especially enhancers, are not only species specific but
also cell-type specific.65 Finally, loss of highly conserved
elements does not always lead to major phenotypic
changes because ‘‘shadow’’ enhancers might compensate
for these functions.66,67 Therefore, phenotype-driven
approaches, such as QT interval GWASs, are important
for understanding cardiac regulatory function.Supplemental Data
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